Simplify Asset Management Inc. Has $880,000 Holdings in Compass Pathways PLC Sponsored ADR $CMPS

Simplify Asset Management Inc. lessened its stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 45.2% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 159,052 shares of the company’s stock after selling 130,948 shares during the period. Simplify Asset Management Inc.’s holdings in Compass Pathways were worth $880,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of CMPS. North Star Investment Management Corp. grew its position in Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after acquiring an additional 7,000 shares during the period. Flax Pond Capital LLC bought a new position in shares of Compass Pathways during the fourth quarter valued at $364,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Compass Pathways during the fourth quarter valued at $47,000. Seven Fleet Capital Management LP acquired a new stake in shares of Compass Pathways in the 4th quarter valued at $276,000. Finally, Corient Private Wealth LLC boosted its stake in shares of Compass Pathways by 3.2% in the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after purchasing an additional 1,200 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Royal Bank Of Canada increased their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. B. Riley Financial started coverage on shares of Compass Pathways in a research report on Friday, April 24th. They issued a “buy” rating and a $17.00 price target on the stock. Morgan Stanley upped their price objective on shares of Compass Pathways from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Wall Street Zen raised shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Compass Pathways has a consensus rating of “Buy” and an average target price of $23.10.

Compass Pathways Stock Performance

Compass Pathways stock opened at $13.62 on Friday. The stock has a 50-day simple moving average of $11.56 and a 200 day simple moving average of $8.37. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways PLC Sponsored ADR has a 12-month low of $3.24 and a 12-month high of $15.40. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -4.32 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. On average, research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.